Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
triglyceride
Biotech
Arrowhead on target in lipid disorder as it pursues Ionis
Arrowhead linked its RNAi drug candidate to improved outcomes through Week 48 to stay on Ionis’ tail in the race to market.
Nick Paul Taylor
Apr 8, 2024 9:37am
Acasti abandons omega-3 filing after 2nd phase 3 flop
Sep 1, 2020 9:20am
Akcea, Pfizer hit midphase goal, but data raise doubts
Jan 29, 2020 7:10am
With phase 2 success, Akcea to test triglyceride-buster in FCS
Jan 22, 2020 10:34am
Acasti blames phase 3 lipid-lowering flop on placebo response
Jan 14, 2020 8:42am
Gemphire pulls the plug on fatty liver disease trial
Aug 10, 2018 10:30am